# Prospective observational study on the accuracy of predictors of high-grade atrioventricular CONDUCTion block after TAVI (CONDUCT-TAVI): Background, trial protocol and significance

\*Karan Rao<sup>1, 2, 3</sup>, Kunwardeep Bhatia<sup>1</sup>, Bernard Chan<sup>1</sup>, Mitchell Cowan<sup>1</sup>, Natasha Saad<sup>1</sup>, Hari Sritharan<sup>1</sup>, Alexandra Baer<sup>2</sup>, Ingrid Bromhead<sup>1</sup>, Usaid Allahwala<sup>1, 2, 3</sup>, Peter Hansen<sup>1, 2</sup> and Ravinay Bhindi<sup>1, 2, 3</sup> <sup>1</sup> Royal North Shore Public Hospital, <sup>2</sup> North Shore Private Hospital, <sup>3</sup> University of Sydney

## Background

High-grade atrioventricular block (HGAVB) is common after TAVI occurring in up to 26% of cases. Patients are typically monitored for 48 hours post-TAVI, however 40% of HGAVB occurs after discharge (delayed).

Delayed HGAVB can cause syncope or sudden unexplained cardiac death in a vulnerable elderly population, and no accurate methods currently exist to identify patients at risk. Protocol

CONDUCT-TAVI is an open-label, prospective observational trial taking place at Royal North Shore and North Shore Private Hospitals in Sydney, Australia [ANZCTR ID: ACTRN12621001700820]

Inclusion Criteria: Consecutive patients for elective TAVI, without prior aortic valve prosthesis or pacemaker

Recruited patients undergo targeted electrophysiology study, including pre and post-TAVI measurement of His-Ventricular (HV) interval and AV Wenckebach cycle length; and receive an implantable loop recorder (ILR) prior to discharge

## **Objectives and Methods**

- 1. Primary objective: Evaluate the diagnostic utility of both novel and previously published HV interval following TAVI
- volume, membranous septum length and fluoroscopic implantation depth



Planned sample size: 205 patients



Follow up: 2 years, with continuous cardiac rhythm monitoring via implantable loop recorders (home monitor)



<u>Current status</u>: Recruitment has commenced and is due for completion by mid-2023. patients recruited so far.


electrophysiological predictors of HGAVB, particularly increase in AV Wenckebach cycle length and

2. Secondary objectives: evaluation of other predictors of HGAVB including ECG parameters, calcium





Interventions	Admission for
Informed Consent	
Inclusion / Exclusion criteria	$\checkmark$
Demographics	$\checkmark$
Medical History	$\checkmark$
Medications List, Height, Weight, Vitals	$\checkmark$
Echocardiogram	$\checkmark$
Pre-procedure CT parameters	$\checkmark$
12 Lead ECG	
Rapid Atrial Pacing	$\checkmark$
Measurement of HV Interval	$\checkmark$
Loop recorder implantation	$\checkmark$
Loop recorder or PPM	
interrogation	



#### Significance

- CONDUCT-TAVI will improve our prediction algorithm for patients at risk of HGAVB and pacemakers after TAVI
- Streamline and optimise TAVI and help shift towards "minimalist TAVI"
- Reduce hospital lengths of stay and improve cost-effectiveness of the procedure
- Improve overall patient outcomes.



n for TAVI		28 days, 6 months, 12 months after TAVI)
/		
/		
/		
		$\checkmark$
		$\checkmark$
		$\checkmark$
/		$\checkmark$
/		
		$\checkmark$
Pre and post T		
		2 year follow up
Loop recorder insertion		Home monitoring

Clinic visits

**Royal North Shore and North Shore Private** Hospitals, Australia